JPWO2022161355A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022161355A5
JPWO2022161355A5 JP2023545206A JP2023545206A JPWO2022161355A5 JP WO2022161355 A5 JPWO2022161355 A5 JP WO2022161355A5 JP 2023545206 A JP2023545206 A JP 2023545206A JP 2023545206 A JP2023545206 A JP 2023545206A JP WO2022161355 A5 JPWO2022161355 A5 JP WO2022161355A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504728A5 (https=
JP2024504728A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/073808 external-priority patent/WO2022161355A1/en
Publication of JP2024504728A publication Critical patent/JP2024504728A/ja
Publication of JP2024504728A5 publication Critical patent/JP2024504728A5/ja
Publication of JPWO2022161355A5 publication Critical patent/JPWO2022161355A5/ja
Pending legal-status Critical Current

Links

JP2023545206A 2021-01-26 2022-01-25 キメラ抗原受容体(car)構築物およびcar構築物を発現するnk細胞 Pending JP2024504728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141621P 2021-01-26 2021-01-26
US63/141,621 2021-01-26
PCT/CN2022/073808 WO2022161355A1 (en) 2021-01-26 2022-01-25 Chimeric antigen receptor (car) constructs and nk cells expressing car constructs

Publications (3)

Publication Number Publication Date
JP2024504728A JP2024504728A (ja) 2024-02-01
JP2024504728A5 JP2024504728A5 (https=) 2025-01-29
JPWO2022161355A5 true JPWO2022161355A5 (https=) 2025-01-29

Family

ID=81327157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545206A Pending JP2024504728A (ja) 2021-01-26 2022-01-25 キメラ抗原受容体(car)構築物およびcar構築物を発現するnk細胞

Country Status (5)

Country Link
US (1) US20240115607A1 (https=)
EP (1) EP4284394A1 (https=)
JP (1) JP2024504728A (https=)
CN (1) CN117062611A (https=)
WO (1) WO2022161355A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN116286660B (zh) * 2022-12-08 2023-10-03 全球细胞控股(广州)有限公司 一种ipsc-(car)自然杀伤细胞、制备方法及其在肿瘤治疗中的应用
AU2024347771A1 (en) * 2023-09-25 2026-02-19 Legend Biotech Ireland Limited Engineered receptors and methods of use thereof
WO2025140265A1 (en) * 2023-12-26 2025-07-03 Wuxi Biologics (Shanghai) Co., Ltd. Combination of chimeric antigen receptor and dap10 in cell therapy
WO2026003135A1 (en) * 2024-06-27 2026-01-02 Genicity Limited Engineered lymphocytes expressing interleukin-15 and interleukin-21 and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPH0746994B2 (ja) 1984-10-04 1995-05-24 味の素株式会社 発酵法によるl−アミノ酸の製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
JPH07501450A (ja) 1991-11-29 1995-02-16 モンサント カンパニー 環状ジグアニレート代謝酵素
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0672161B1 (en) 1992-11-05 1999-09-22 Xyrofin Oy Recombinant method and host for manufacture of xylitol
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3709564B2 (ja) 1994-08-30 2005-10-26 味の素株式会社 L−バリン及びl−ロイシンの製造法
JP3966583B2 (ja) 1997-06-23 2007-08-29 協和醗酵工業株式会社 発酵法によるl−アミノ酸の製造法
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
NL2006359C2 (en) 2011-03-08 2012-04-24 Bird Engineering B V Genetically modified cell and process for use of said cell.
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9913627B2 (en) * 2013-01-29 2018-03-13 Becton, Dickinson And Company Specimen collection container having a fluid separation chamber
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
CN114181960B (zh) 2015-10-09 2024-08-23 美天施生物科技有限公司 嵌合抗原受体和使用方法
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
WO2019079339A1 (en) 2017-10-18 2019-04-25 Avalon Flaviviral Therapeutics (Hk) Limited COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
WO2020055368A2 (en) 2018-09-12 2020-03-19 Istanbul Medipol Universitesi Usage of terpenic coumarin derived molecules in treating viral diseases
SG11202104287RA (en) * 2018-11-06 2021-05-28 Univ Washington Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same
AU2020232691B2 (en) * 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
KR20210145179A (ko) * 2019-03-22 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 스위치 가능한 키메라 항원 수용체-조작된 인간 자연 살해 세포
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof

Similar Documents

Publication Publication Date Title
JP2025065142A5 (https=)
EP3472205B1 (en) Chimeric antigen receptor
JP2021177771A5 (https=)
CA2978381C (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
JP2022002546A (ja) 細胞
US20200255494A1 (en) Cell
JP2019150066A5 (https=)
JP2020517295A5 (https=)
JP2021527689A (ja) キメラ膜貫通タンパク質及びその使用
JP2021536265A5 (https=)
KR20180009738A (ko) 키메라 항원 수용체
JP2020513754A5 (https=)
JP2015513920A5 (https=)
CN109053899B (zh) 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
JP2018526033A5 (https=)
WO2015173112A1 (en) Glypican-3-specific t-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
TW201841944A (zh) 4-1bbl變異體及包含其之融合蛋白
JP2026500718A (ja) B7-h3を標的とする抗体または抗体断片、およびキメラ抗原受容体免疫細胞療法の分野におけるその使用
JPWO2022133169A5 (https=)
TW202144396A (zh) 抑制性嵌合受體架構
CN112996819B (zh) 细胞分选系统及使用方法
Guo et al. Chimeric non-antigen receptors in T cell-based cancer therapy
JPWO2020037066A5 (https=)
JPWO2022161355A5 (https=)